Supriya Lifescience Ltd (SUPRIYA) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company demonstrated a strong recovery, achieving a 20% year-on-year revenue growth, signaling a return to its expected trajectory after a muted first quarter caused by plant maintenance and de-bottlenecking activities.
- Exports continue to be the primary driver of the business, contributing 81% of the total revenue for the quarter, underscoring the company's strong position in international markets.
- Significant progress in backward integration was highlighted, with 79% of Q2 FY26 revenues coming from fully integrated products, which enhances cost efficiency and operational control.
- The new Ambernath facility is advancing as planned, with validation campaigns underway and commercial contributions from liquid anesthetics and oral solids expected to commence in Q4 FY26.
- Management reiterated its full-year guidance of approximately 20% annual revenue growth with EBITDA margins maintained in the 33%-35% range, expressing confidence in a stronger performance in the second half of the year.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.